Navigation Links
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Date:1/18/2008

tially or completely stop the NNRTI from binding to the reverse transcriptase enzyme, causing the drug to lose effectiveness. As with other HIV medications, patients can develop resistance to INTELENCE; for more information see the resistance section below.

DUET-1 and -2 Study Design

The DUET-1 and -2 studies, identical in design but conducted in different regions, assessed the 24-week efficacy and safety of INTELENCE in combination with a background regimen (BR) in treatment-experienced adult HIV-1 patients with documented evidence of NNRTI and PI resistance. They were large randomized, controlled studies with a primary endpoint of less than 50 copies/mL (known as undetectable viral load). IAS-USA treatment guidelines define less than 50 copies/mL as the goal of therapy for treatment-experienced patients when two or more potent drugs are identified.

Patients with HIV-1 who were eligible for the DUET studies had a viral load of greater than 5,000 copies/mL, while on a stable antiretroviral therapy regimen for at least eight weeks and had evidence of at least one NNRTI resistance-associated mutation, either at screening or from prior resistance tests, as well as evidence of three or more primary PI mutations (D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, V82A/F/L/S/T, I84V, N88S, or L90M) at screening.

DUET-1 and -2 Efficacy

Participants in the DUET studies were randomized to receive INTELENCE 200 mg twice daily (599 patients) or placebo (604 patients), each given in addition to a BR. For all patients, the BR included darunavir/ritonavir, plus at least two investigator-selected antiretroviral drugs (N(t)RTIs with or without enfuvirtide).

The 24-week pooled analysis of the DUET studies showed the following results for INTELENCE plus BR vs. placebo plus BR:

-- Significantly more patients in the INTELENCE arm achieved undetectable

viral load (less than 50 copies/mL); 59.8 percent vs. 40.2 percent


'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
2. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
3. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
5. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
6. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
7. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
10. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
11. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 SoundConnect , an ... is proud to announce the strategic additions of ... their Boston, Charleston and Atlanta offices. SoundConnect’s ... demand for hosted solutions, collaboration and mobility that ... cost. , SoundConnect was founded in 2004, with ...
(Date:7/29/2014)... July 29, 2014 The advanced optical ... brain that are driving a revolution in the neurosciences ... peer-reviewed journal published by SPIE, the international society ... coincides with the launch of the BRAIN Initiative in ... that lay out a vision for and provide examples ...
(Date:7/29/2014)... Cheshire Cat: Can a particle be separated from its ... Communications , published the results of the first Cheshire ... conducted by Chapman University in Orange, CA, and Vienna ... a cat without a grin," thought Alice in Wonderland, ... curious thing I ever saw in my life!" Alice,s ...
(Date:7/29/2014)... July 29, 2014  The Society for Clinical ... updated program for the 9 th annual ... in Amelia Island , Florida.  The focus ... remains unchanged, however, the topics and format will ... opportunity among all stakeholders with a continued focus ...
Breaking Biology Technology:SoundConnect Organization and Culture is Evolving 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3
... , AUSTIN, Texas, July 27 Patton ... of injection port therapy, announced today that they have entered into ... medical devices used in the treatment of diabetes. , , ... The two companies are working together to design and develop the ...
... SAN DIEGO, July 24 Orexigen Therapeutics, Inc. (Nasdaq: ... exercised their overallotment option to purchase an additional 1,500,000 shares ... public offering that priced on July 23, 2009. Including ... a public offering price of $7.50 per share, resulting in ...
... , , , ... , NES-ZIONA, Israel, July 24 PROLOR Biotech, Inc. (OTC Bulletin ... purchase agreements with private investors to sell up to $10 million of the ... per share. As part of the agreements, the company closed on the ...
Cached Biology Technology:Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections 2Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections 3Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters 2PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 2PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 3PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 4
(Date:7/29/2014)... PARIS, 29 JULY 2014 With thirty days to ... for the FEBS-EMBO 2014 Conference are well underway. The ... Biochemical Societies (FEBS), EMBO, and the French Society for ... Saturday, 30 August to Thursday, 4 September at the ... 2014 Conference is the largest meeting for the life ...
(Date:7/29/2014)... study from UC San Francisco is the first to ... overtime and accelerate cellular aging, these negative effects may ... sleeping well. , "The study participants who exercised, ... than the ones who didn,t maintain healthy lifestyles, even ... author Eli Puterman, PhD, assistant professor in the department ...
(Date:7/28/2014)... people in the United States have a circulatory problem ... be painful and may even require surgery in serious ... wasting and, in turn, limb amputation. , At The ... Medical School, scientists tested a non-surgical preventative treatment in ... associated with increased blood circulation. Their proof-of-concept study ...
Breaking Biology News(10 mins):Counting down to FEBS-EMBO 2014 in Paris, France 2Healthy lifestyle may buffer against stress-related cell aging, study says 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... 2010 UT Southwestern Medical Center researchers have found new ... susceptible to stress than others. In a study of ... event, animals that were more susceptible to stress exhibited enhanced ... brain. Specifically, the cells that these animals produced after a ...
... Hemophilia, a disease linked with legends of European monarchs, frail ... people today. And the very treatments that can help ... treatment is infusion with an expensively produced protein that helps ... system fights the therapy, and in a subset of those, ...
... N.J. ―The Center for Secure and Resilient Maritime Commerce (CSR) ... report. Stevens was named by the US Department ... Centers of Excellence and was selected to lead a national ... 11 universities to partner with the DHS and serve as ...
Cached Biology News:New brain nerve cells key to stress resilience, UT Southwestern researchers find 2New brain nerve cells key to stress resilience, UT Southwestern researchers find 3Researchers harness the power of plants to fight hemophilia 2Researchers harness the power of plants to fight hemophilia 3Researchers harness the power of plants to fight hemophilia 4
WIF-1 (N-20)...
... Strong reactivity with rat (100%), ... guinea pig (48%). Slight ... Specificity confirmed by Western blot ... rat Gia-1, Gia-2, rat Gia-3, ...
VEGF Receptor-2, phospho-specific (Tyr996)...
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
Biology Products: